Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Kinaxo Biotechnologies GmbH. (3/15/11). "Press Release: Kinaxo Extends Collaboration with Takeda". Martinsried.

Organisations Organisation Kinaxo Biotechnologies GmbH
  Today Evotec (München) GmbH
  Group Evotec (Group)
  Organisation 2 Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
Products Product PhosphoScout® technology
  Product 2 drug development services
Index term Index term Takeda–Evotec: mass spectrometry services, 201103– collab Kinaxo will apply PhosphoScout techn to assist drug developm research of Takeda
Person Person Jenne, Andreas (RSP Systems 201805– CEO before NEO New Oncology + Blackfield + Kinaxo)
     


KINAXO Biotechnologies GmbH announced today that it has entered a second collaboration with Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout® to assist in research of drugs under development at Takeda. This will allow Takeda to take early educated decisions on drug efficacy and safety. Financial details of the agreement were not disclosed.

PhosphoScout® enables quantitative analysis of cellular phosphoproteomes on a global scale. Since signal transmission in eukaryotic cells is mainly regulated by reversible protein phosphorylation, comprehensive analysis of phosphoproteome modulation in response to drug treatment provide valuable insights into a drug's mode of action. Furthermore, PhosphoScout® can identify differentially regulated phosphorylation sites in vivo that may serve as pharmacodynamic or drug response biomarkers in clinical trials.

PhosphoScout® utilizes state-of-the-art mass spectrometry methods enabling unbiased quantification of approx. 15,000 phosphorylation sites in a single experiment. Proprietary bioinformatic software tools are applied to visualize the drug's effects on cellular signal transduction pathway and help identify phospho-protein biomarkers.

Dr. Andreas Jenne, KINAXO's CEO said: "We are very pleased to continue our collaboration with Takeda, a world leading healthcare company, and look forward to supporting Takeda's efforts in developing drugs. This collaboration once again demonstrates the power of our PhosphoScout® platform in drug discovery and development."


About KINAXO

KINAXO Biotechnologies GmbH, based in Munich/Martinsried, supports pharma companies in developing targeted drugs. Our service offering includes drug mode-of-action analysis, cellular target profiling, target deconvolution, and biomarker discovery.

On February 9, 2011 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced the signing of a definitive agreement to acquire all shares in KINAXO Biotechnologies GmbH. Within Evotec KINAXO will become a centre of excellence for mass spectrometry based chemical proteomics and phosphoproteomics technologies. The acquisition confirms Evotec's leading position as fully integrated drug discovery and early development partner for pharmaceutical and biotechnology companies.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top